Acorda Therapeutics, Inc. Nasdaq




Biotechnology & Medical Research

Delayed Nasdaq 11:55:40 2024-05-22 am EDT 5-day change 1st Jan Change
0.76 USD -10.59% Intraday chart for Acorda Therapeutics, Inc. +100.00% -94.96%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Chart Acorda Therapeutics, Inc.
More charts
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
More about the company
  1. Stock Market
  2. Equities
  3. ACOR.Q Stock
  4. ACOR Stock
  5. News Acorda Therapeutics, Inc.
  6. Sector Update: Health Care Stocks Slide Late Afternoon
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.